Astellas’s ‘Vesicare’ filed lawsuit for infringement by CorePharm Bio
On the 4th, Astellas Korea(CEO Hae-do Jung) announced it jointly filed a patent infringement prohibition trial against CorePharm Bio with Astellas Korea to the Seoul Central District Court.
The trial is in regards to ‘Vesicare,’ the Astellas’s hypersensitive bladder treatment.
The Japanese Ast...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
